Acura Pharmaceuticals Inc. (NASDAQ:ACUR)
| CAPS Rating |
|
|---|---|
| Open | $3.25 |
| Previous Close | $3.24 |
| Daily Range | $3.24 - $3.38 |
| 52-Week Range | $2.28 - $6.80 |
| Market Cap | $146.82M |
| P/E Ratio | 21.50 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 67,317 |
| Average Daily Volume | 0 |
ACUR
VS S&P 500 (SPY)
How do you think ACUR will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
ACUR Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
ACUR News and Commentary
- US STOCK FUTURES: HOT STOCKS TO WATCH – SmartMoney
- US STOCK FUTURES: HOT STOCKS TO WATCH -2- – SmartMoney
- US STOCK FUTURES: HOT STOCKS TO WATCH – SmartMoney
- Acura Pharma: Pfizer Starting To Sell Pain Drug With Acura Technology – SmartMoney
- Durect Investors Feel the Pain – The Motley Fool
- Like It (Almost) Never Happened – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Double Ouch! 2 Monster Drops in 2 Trading Days – The Motley Fool
- Pain Therapeutics Shares Plunged: What You Need to Know – The Motley Fool
- Come On, Pfizer, Not Even a Little Hint? – The Motley Fool
- Pain Therapeutics Shares Plunged: What You Need to Know – The Motley Fool
- Pain Therapeutics, Durect Shares Plunge on Pain Drug Rejection – Minyanville
- FDA Rejects Drug Application For Pain Killer From Pfizer, Pain Therapeutics – SmartMoney
- Will the FDA Approve Pfizer and Pain Therapeutics' Remoxy? – The Motley Fool
- Why Did My Stock Just Die? – The Motley Fool
- Bullish Biotech: 5 Biotech Firms Making Great Strides – The Motley Fool
- Pfizer's Pain-Free FDA Approval. More to Come? – The Motley Fool
- 2nd UPDATE: FDA Approves Pain Offering From Pfizer, Acura Pharma – SmartMoney
- Mid-Day Update: Stocks Shake Off Greece Worries to Sit Higher at Session's Half; Commodities Mixed – NASDAQ
- US Indexes Gains Despite Greece Worries; Commodities Mixed at the Session's Half – NASDAQ
RSS Headlines
Fool UK
